$3.67
6.69% yesterday
NYSE, Jun 06, 10:13 pm CET
ISIN
CH0499880968
Symbol
ADCT
Sector
Industry

Adc Therapeutics SA Stock price

$3.67
+2.38 184.50% 1M
+0.54 17.25% 6M
+1.68 84.42% YTD
+0.19 5.46% 1Y
-31.58 89.59% 5Y
-25.98 87.62% 10Y
-25.98 87.62% 20Y
NYSE, Closing price Fri, Jun 06 2025
+0.23 6.69%
ISIN
CH0499880968
Symbol
ADCT
Sector
Industry

Key metrics

Market capitalization $363.98m
Enterprise Value $609.89m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.04
P/S ratio (TTM) P/S ratio 4.80
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -37.54%
Revenue (TTM) Revenue $75.82m
EBIT (operating result TTM) EBIT $-125.51m
Free Cash Flow (TTM) Free Cash Flow $-136.67m
Cash position $194.70m
EPS (TTM) EPS $-1.39
P/E forward negative
P/S forward 4.70
EV/Sales forward 7.87
Short interest 5.55%
Show more

Is Adc Therapeutics SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Adc Therapeutics SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Adc Therapeutics SA forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Adc Therapeutics SA forecast:

Buy
100%

Financial data from Adc Therapeutics SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
76 76
38% 38%
100%
- Direct Costs 5.50 5.50
8% 8%
7%
70 70
39% 39%
93%
- Selling and Administrative Expenses 83 83
53% 53%
109%
- Research and Development Expense 113 113
47% 47%
149%
-122 -122
56% 56%
-161%
- Depreciation and Amortization 3.75 3.75
326% 326%
5%
EBIT (Operating Income) EBIT -126 -126
55% 55%
-166%
Net Profit -150 -150
61% 61%
-198%

In millions USD.

Don't miss a Thing! We will send you all news about Adc Therapeutics SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adc Therapeutics SA Stock News

Neutral
PRNewsWire
5 days ago
LAUSANNE, Switzerland , June 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 107,550 of the Company's common shares to two new employees on June 2, 2025 (each, a "Grant"). The Grants were offered as materi...
Neutral
PRNewsWire
23 days ago
LAUSANNE, Switzerland , May 15, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two upcoming investor conferences: RBC Capital Markets Global Healthcare ConferenceDate: May 21, 2025 Presentation Time: 10:30-10:55 a.m. ET Format: Fireside ChatSpeaker: Ameet Mallik...
Neutral
Seeking Alpha
24 days ago
ADC Therapeutics SA (NYSE:ADCT ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Corporate Participants Marcy Graham - Investor Relations Officer Ameet Mallik - Chief Executive Officer Mohamed Zaki - Chief Medical Officer Pepe Carmona - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Sudan Loganathan - Stephens Operator Good morning, ladies and gentlemen, and...
More Adc Therapeutics SA News

Company Profile

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Head office Switzerland
CEO Ameet Mallik
Employees 264
Founded 2011
Website adctherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today